Chemotherapy induced pseudo-cirrhosis in a breast cancer patient with liver metastasis: A case report and review of the literature
Bashar Fteiha
Case Reports in Internal Medicine, 2016
View PDFchevron_right
Pseudocirrhosis of Breast Cancer Metastases to the Liver Treated by Chemotherapy
Yoon Myat Ko Ko
Cancer Research and Treatment, 2014
View PDFchevron_right
Effect of doxorubicin and cyclophosphamide regimen versus taxane on liver enzymes in Iraqi women with breast cancer
zainab anber
Biomedical Research, 2018
View PDFchevron_right
Pseudocirrhosis: A Case Series and Literature Review
Abimbola Aderinto
Case Reports in Gastroenterology, 2016
View PDFchevron_right
Assessment of Liver Morbidity in Breast Cancer Patients Receiving Chemotherapy in Suez Canal University Hospitals
Mahmoud Sheded
Afro-Egyptian Journal of Infectious and Endemic Diseases
View PDFchevron_right
Metastatic Breast Cancer Presenting as Acute Liver Failure
Dina Marzio
Transplantation Case Reports, 2020
View PDFchevron_right
Taxane Combination Chemotherapy in Breast Cancer: Experience from a Tertiary Cancer Centre in India
Reena Nair
Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology
View PDFchevron_right
Methotrexate-associated liver toxicity in a patient with breast cancer: Case report and literature review
John-paul Bogers
The Netherlands Journal of Medicine
View PDFchevron_right
Effect of Breast Cancer Molecular Subtypes on Survival in Patients with Liver Metastases
Enas A Elkhouly
Research in Oncology, 2014
View PDFchevron_right
Clinical outcome of breast cancer patients with liver metastases alone in the anthracycline-taxane era: a retrospective analysis of two prospective, randomised metastatic breast cancer trials
Ferhat Telli, Serdar Turhal, Selcuk Seber
European Journal of Cancer, 2003
View PDFchevron_right
Clinical Outcomes of Metastatic Breast Cancer in Patients Having Both Pseudocirrhosis and Portal Hypertension with Evident Varices
Ketty Herrera-Mendoza
2021
View PDFchevron_right
Chemotherapy and Hormone Therapy for Breast Cancer and Complications
seema devi
International Journal of Medical and Biomedical Studies
View PDFchevron_right
Fulminant Liver Failure in a Patient Affected by Polycystic Liver Disease and Liver Metastases from Breast Carcinoma
Davide Santeufemia
Tumori Journal
View PDFchevron_right
A Phase II Randomized Study of Lapatinib Combined With Capecitabine, Vinorelbine, or Gemcitabine in Patients With HER2-Positive Metastatic Breast Cancer With Progression After a Taxane (Latin American Cooperative Oncology Group 0801 Study)
Yeni Nerón
Clinical Breast Cancer, 2016
View PDFchevron_right
Therapeutic intervention in patients with breast carcinoma, metastatic and her-2 over expression: case report
Ana Cristina Herrera
Journal of Cancer Prevention & Current Research, 2018
View PDFchevron_right
Taxanes in adjuvant breast cancer treatment
Ljubica Vazdar
Libri Oncologici : Croatian Journal of Oncology, 2018
View PDFchevron_right
A case–control study of non-alcoholic fatty liver disease in breast cancer
Ibrahim Adaletli
Medical Oncology, 2007
View PDFchevron_right
Bevacizumab in combination with a taxane for the first-line treatment of HER2-negative metastatic breast cancer
Marta Soares
Health technology assessment (Winchester, England), 2011
View PDFchevron_right
Five years of stable disease with maintenance therapy using bevacizumab and tamoxifen in a patient with metastatic breast cancer
Maria Mazzei
Cancer biology & therapy, 2015
View PDFchevron_right
A phase II randomized study of lapatinib in combination with capecitabine, vinorelbine or gemcitabine in patients with HER2 positive metastatic breast cancer who progressed after a taxane (LACOG 0801)
Henry Gomez
Clinical Breast Cancer, 2015
View PDFchevron_right
An evaluation of Hepatotoxicity in Breast cancer patients receiving Injection Doxorubicin
Damodar Gaddam
View PDFchevron_right
Introducing taxanes in the adjuvant treatment of breast cancer: expectations and reality
L. Orlando
The Breast, 2000
View PDFchevron_right
Benefit from adjuvant taxanes and endocrine responsiveness in breast cancer
John Mackey
The Breast, 2007
View PDFchevron_right
HER2-Positive Conversion in a Metastatic Liver Focus in Late Recurrent Breast Cancer
Yasuo Hozumi
Case Reports in Oncology, 2019
View PDFchevron_right
Late Liver Metastasis 20 Years After the Initial Diagnosis: A Case Report of Metachronous Hormone Dependent Tumors of Breast and Endometrium
Milica Stankovic
2021
View PDFchevron_right
Occult breast malignancy masquerading as acute hepatic failure
Katie Farah
Gastroenterology & hepatology, 2011
View PDFchevron_right
Prognostic factors for patients with hepatic metastases from breast cancer
Sarah Pinder
British journal of cancer, 2003
View PDFchevron_right
Gemcitabine and taxanes in metastatic breast cancer: a systematic review
Vinay Gudena
Therapeutics and clinical risk management, 2008
View PDFchevron_right
Bevacizumab in the Treatment of Metastatic Breast Cancer
mauricio Cabello Escobar
Breast Care, 2007
View PDFchevron_right
First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2251 patients
Erion Dobi
Annals of Oncology, 2011
View PDFchevron_right
Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: The trastuzumab and vinorelbine or taxane study
Aparna Keshaviah
Cancer, 2007
View PDFchevron_right
The combination of gemcitabine and vinorelbine is an active regimen as second-line therapy in patients with metastatic breast cancer pretreated with taxanes and/or …
Vincenzo Accurso
Breast cancer research …, 2003
View PDFchevron_right